Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022

Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022
CANNANNEW REPORT

­— GFB-024 is a novel precision medicine candidate intended to treat patients with severe insulin resistant diabetic nephropathy (SIRDN) and cannabinoid 1 (CB1) pathway overactivation — CAMBRIDGE, Mass.–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that it will present initial data from its Phase 1 clinical trial of GFB-024 in a poster presentation at the American Diabetes Association (ADA) 82nd Scientific Sessions, taking place June 3-7 in New Orleans, LA, and an oral presentation at the Endocrine Society’s Annual Meeting, ENDO 2022, taking place June 11-14 in Atlanta, GA. Both meetings also have a virtual component. Goldfinch Bio is developing GFB-024, a peripherally restricted cannabinoid 1 (CB1) inverse agonist monoclonal antibody, for patients with severe insulin resistant diabetic nephropathy (SIRDN) and CB1 pathway overactivation. Patients who present with severe insulin-resistant diabetes (SIRD) have a rapidly progressing form of DN and are at particularly high risk of developing diabetic kidney disease and progression to kidney failure. In addition, elevated CB1 signaling has been shown to induce podocyte death, proteinuria and tubular cellular injury, resulting in serious harm to the kidney. GFB-024 has the potential to provide disease-modifying effects in the kidney while treating the underlying metabolic dysfunction in obese patients without the CNS side-effects seen by prior small molecule CB1 antagonists. GFB-024 has demonstrated podocyte protective effects in preclinical models, while clinical data from first generation CB1 antagonists have demonstrated metabolic benefits, such as reduced cholesterol, glucose, and HbA1c, in third-party clinical trials, which may also lead to additional beneficial kidney effects. The double-blind, randomized, placebo-controlled Phase 1 trial is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-ascending doses of GFB-024 in overweight and obese healthy volunteers, as well as to explore candidate…

Excerpt only …
READ MORE BELOW
Source : Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.